A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Piclidenoson (Primary) ; Apremilast
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms COMFORT
  • Sponsors Can-Fite BioPharma
  • Most Recent Events

    • 07 Aug 2017 According to a Can-Fite BioPharma media release, this trial is expected to initiate in early 2018.
    • 07 Aug 2017 According to a Can-Fite BioPharma media release, based on the favorable safety data from cardiodynamic trial CTP#700287672 company is cleared to initiate this study.
    • 30 May 2017 According to a Can-Fite BioPharma media release, the company expects that this pivotal Phase III study will serve as the first of two pivotal studies required for EMA drug approval.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top